Clinical Trial Update: A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL [Phase 2]

View source ↗

Summary

Phase II trial evaluating alemtuzumab and rituximab in patients with previously untreated chronic lymphocytic leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Northwestern University | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-10-19